Terms: = Lymphoma AND EML4, ENSG00000143924, 27436 AND Treatment
318 results:
1. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure.
Yang C; Zeng R; Zha Y; Li Y; Wang T; Zhao R; Li M; Zhang J
Front Immunol; 2024; 15():1360671. PubMed ID: 38380327
[TBL] [Abstract] [Full Text] [Related]
2. Longitudinal plasma proteomic profiling of eml4-ALK positive lung cancer receiving ALK-TKIs therapy.
Wang S; Hao X; Dai L; Lou N; Fan G; Gao R; Yang M; Xing P; Liu Y; Wang L; Zhang Z; Yao J; Tang L; Shi Y; Han X
Lung Cancer; 2024 Mar; 189():107503. PubMed ID: 38359741
[TBL] [Abstract] [Full Text] [Related]
3. Mitoxantrone and abacavir: An ALK protein-targeted in silico proposal for the treatment of non-small cell lung cancer.
Faya Castillo JE; Zapata Dongo RJ; Wong Chero PA; Infante Varillas SF
PLoS One; 2024; 19(2):e0295966. PubMed ID: 38319906
[TBL] [Abstract] [Full Text] [Related]
4. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-eml4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract] [Full Text] [Related]
5. A case of inflammatory myofibroblastic tumor harboring eml4-ALK fusion with a brain metastasis responding to alectinib.
Sakoda S; Tanaka K; Koga Y; Mikumo H; Tsuchiya-Kawano Y; Harada E; Tamiya S; Okamoto I
Thorac Cancer; 2024 Feb; 15(5):415-418. PubMed ID: 38213097
[TBL] [Abstract] [Full Text] [Related]
6. Left total pneumonectomy performed after alectinib treatment for anaplastic lymphoma kinase-positive lung adenocarcinoma: a case report.
Wang Z; Shi Y; Zhang P; Chen Y
Chin Clin Oncol; 2023 Dec; 12(6):70. PubMed ID: 38195077
[TBL] [Abstract] [Full Text] [Related]
7. Crizotinib combined with bronchoscopic interventional treatment in ALK-positive inflammatory myofibroblastic tumor of left main stem bronchus: a case report.
Zhang P; Wang C; Lv Z; Du M; Xu R
J Cardiothorac Surg; 2023 Nov; 18(1):318. PubMed ID: 37950305
[TBL] [Abstract] [Full Text] [Related]
8. Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report.
Li J; Liu J; Zhang G; Hu W; Wang X; Liu J
Am J Case Rep; 2023 Nov; 24():e942150. PubMed ID: 37934724
[TBL] [Abstract] [Full Text] [Related]
9. Transformation of NSCLC to SCLC harboring eml4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract] [Full Text] [Related]
10. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease.
Sun W; Zheng J; Zhou J; Zhou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 52(5):583-587. PubMed ID: 37899398
[TBL] [Abstract] [Full Text] [Related]
11. A Functional Genomics Review of Non-Small-Cell Lung Cancer in Never Smokers.
Hamouz M; Hammouz RY; Bajwa MA; Alsayed AW; Orzechowska M; Bednarek AK
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686122
[TBL] [Abstract] [Full Text] [Related]
12. Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.
Yang Y; Lu B; Hu M; Wang Q; Jiang M; Zhang T; Liu Z
BMC Pulm Med; 2023 Sep; 23(1):319. PubMed ID: 37658352
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy of Lorlatinib in treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to eml4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A; Martini JF; Jassem J; Kim SW; Chang GC; Shaw AT; Shepard DA; Dall'O' E; Polli A; Thurm H; Zalcman G; Garcia Campelo MR; Penkov K; Hayashi H; Solomon BJ
J Thorac Oncol; 2023 Nov; 18(11):1581-1593. PubMed ID: 37541389
[TBL] [Abstract] [Full Text] [Related]
14. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Yoshida T; Kumagai T; Toyozawa R; Katayama R; Nishio M; Seto T; Goto K; Yamamoto N; Ohe Y; Kudou K; Asato T; Zhang P; Nakagawa K
Cancer Sci; 2023 Sep; 114(9):3698-3707. PubMed ID: 37434391
[TBL] [Abstract] [Full Text] [Related]
15. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
Ou SI; Lee ATM; Nagasaka M
Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318
[TBL] [Abstract] [Full Text] [Related]
16. eml4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries.
Elshatlawy M; Sampson J; Clarke K; Bayliss R
Mol Oncol; 2023 Jun; 17(6):950-963. PubMed ID: 37149843
[TBL] [Abstract] [Full Text] [Related]
17. Successful treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic lymphoma Kinase Fusion Gene.
Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
[TBL] [Abstract] [Full Text] [Related]
18. Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib.
Hu Q; Liao Y; Cao J; Fang B; Yun SY; Kinose F; Haura EB; Lawrence HR; Doebele RC; Koomen JM; Rix U
Chembiochem; 2023 Jun; 24(11):e202200766. PubMed ID: 36922348
[TBL] [Abstract] [Full Text] [Related]
19. Multisystem ALK-positive histiocytosis: a multi-case study and literature review.
Liu W; Liu HJ; Wang WY; Tang Y; Zhao S; Zhang WY; Yan JQ; Liu WP
Orphanet J Rare Dis; 2023 Mar; 18(1):53. PubMed ID: 36915094
[TBL] [Abstract] [Full Text] [Related]
20. [Lung Squamous Cell Carcinoma with eml4-ALK Fusion and TP53 Co-mutation
Treated with Ensartinib: A Case Report and Literature Review].
Lv D; Xu C; Wang C; Sang Q
Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):78-82. PubMed ID: 36792084
[TBL] [Abstract] [Full Text] [Related]
[Next]
